Menu Back toSession-0302-The-Feasibility-of-Initiating-Clinical-Trials-by-Single-IRB-Approving-in-China
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
The 7th DIA China Annual Meeting
Session 0302 The Feasibility of Initiating Clinical Trials by Single IRB Approving in China
Shuting LI, MD
- Deputy Director
- GCP Alliance, China, China
- Global Monitoring Operation Country Head
- Novartis Pharmaceuticals, China
- Quintiles Medical Development (Shanghai) Co. Ltd, China
- Vice Director, Clinical Pharmacology Research Center
- Peking Union Medical College Hospital, China
What will be reviewed in multicenter ethical review units should review what?
- Director,Drug Clinical Trial Institute Office
- Xinan Hospital of Army Medical University, China
- Vice President, Research & Clinical Development
- Shenzhen Chipscreen Biosciences, Ltd., China
The feasibility of center ethical review implementation in China
- Executive Director
- GlobalMD, United States